Hydofon (Hydromorphone Hydrochloride)

Hydofon is prescribed for the management of moderate to severe pain when alternative analgesics are insufficient or not tolerated. It is commonly used in postoperative settings, cancer-related pain, and in patients requiring opioid rotation.

• Acute postoperative pain
• Cancer-related pain
• Severe chronic pain unresponsive to non‑opioid analgesics
• Pain requiring opioid rotation or breakthrough dosing
• Situations where rapid analgesia is needed under close supervision

• Hydromorphone hydrochloride exerts its analgesic effect by binding selectively to μ‑opioid receptors in the central nervous system. This agonist activity inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and modulates pain signal transmission in the spinal cord and brain. The resulting decrease in nociceptive processing produces potent analgesia, while also influencing respiratory and gastrointestinal pathways. The drug’s high lipid solubility facilitates rapid crossing of the blood‑brain barrier, contributing to its quick onset of action.

Hydromorphone may cause a range of adverse reactions, varying in frequency and severity.

Common

• Constipation
• Nausea
• Drowsiness
• Dizziness
• Dry mouth
• Mild itching

Serious

• Respiratory depression
• Severe hypotension
• Acute opioid intoxication
• Allergic reactions such as rash or angioedema

When prescribing Hydofon, clinicians should evaluate several safety factors to minimize risk.

• Assess patient’s respiratory function before initiating therapy.
• Use the lowest effective dose and limit duration to reduce dependence risk.
• Avoid use in patients with known hypersensitivity to hydromorphone or other opioids.
• Caution in individuals with head injury, increased intracranial pressure, or severe hepatic impairment.
• Monitor for signs of sedation, confusion, or respiratory compromise, especially in the elderly.
• Educate patients about proper storage and disposal to prevent misuse.

Hydofon can interact with other medications, potentially altering its safety profile.

Avoid

• Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates, alcohol) due to additive respiratory depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase hydromorphone plasma levels.
• MAO inhibitors within 14 days, as they can precipitate severe reactions.

Use with caution

• CNS stimulants (e.g., antidepressants, antipsychotics) that may alter opioid effects.
• Diuretics and antihypertensives, which can enhance hypotensive effects.
• Other opioids, requiring careful dose adjustment to avoid overdose.